 | Up a level |
Chamuleau, Martine E D; Stenner, Frank; Chitu, Dana A; Novak, Urban; Minnema, Monique C; Geerts, Paul; Stevens, Wendy B C; Zenz, Thorsten; van Imhoff, Gustaaf W; Wu, Ka Lung; Demandt, Astrid M P; Kersten, Marie Jose; Terpstra, Wim E; Tick, Lidwine W; Deeren, Dries; Van Den Neste, Eric; Gregor, Michael; Veelken, Hendrik; Böhmer, Lara H; Caspar, Clemens B; ... (2023). R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. The Lancet. Haematology, 10(12), e966-e975. Elsevier 10.1016/S2352-3026(23)00279-X
Kamdar, Manali; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Maloney, David G; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Stepan, Lara; Ogasawara, Ken; Mack, Timothy; ... (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), pp. 2294-2308. Elsevier 10.1016/S0140-6736(22)00662-6
